Drugs / RANOSIDENIB
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07025018 | Jul 2025 → Dec 2026 expected | glioma | Hutchmed | Recruiting | No outcome recorded |
| Phase 1 | NCT06671873 | Nov 2024 → Feb 2025 | — | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT04764474 | Apr 2021 → Jan 2025 | — | Hutchmed | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04762602 | Feb 2021 → Feb 2025 | — | Hutchmed | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04272957 | May 2020 → Jun 2021 | acute myeloid leukemia | Hutchison Medipharma Limited | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06387069 | Apr 2024 → Dec 2028 expected | acute myeloid leukemia | Hutchmed | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-09 | Hutchison Medipharma Limited | Results HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings hutch-med.com ↗
Based on PD, pharmacokinetic (“PK”), and preliminary clinical findings, a recommended Phase II dose was nominated for the dose expansion phase of the study. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-14 | Hutchison Medipharma Limited | HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China hutch-med.com ↗ |
| 2023-06-09 | Hutchison Medipharma Limited | HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings hutch-med.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RANOSIDENIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068069 ↗ |
| Known as | HMPL-306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06387069 ↗ |
| Action | Inhibit | “HMPL-306 has equally high inhibitory activity against mutated isocitrate dehydrogenases 1 and 2 (mIDH1/2).” PMID 39892383 ↗ Jan 2025 |
| Modality | Small molecule | “IDH small molecule inhibitor” NCT07025018 ↗ |
| Route | Oral | “HMPL-306 administered continuously as a single agent orally every day” NCT04272957 ↗ |
| Target | IDH1 | “HMPL-306 has equally high inhibitory activity against mutated isocitrate dehydrogenases 1 and 2 (mIDH1/2).” PMID 39892383 ↗ Jan 2025 |